Summary
Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates are more engaged with the scientific and research community in comparison to some other disease and patient focus groups. By collaborating with rare disease patients, their families and various stakeholders involved on the design, positioning and subsequent enrollment of clinical trials, studies can be completed faster and more efficiently. PRA Health Sciences' Scott Schliebner (Vice President, Rare Diseases, Scientific Affairs) and Altair da Silva (Senior Manager, Patient Access and Recruitment Services) are joined by Neil Weisman (Executive Vice President and General Manager at Blue Chip Marketing) to discuss the patient voice and the importance of patient and caregiver insight.
You may also be interested in:
Resource
COVID-19 Impact on Rare Disease Clinical Trials
Rare disease patient organizations are coping with a broad range of other organizational challenges, including reduced funding, canceled fundraising…
page
Clinical Trial Manager
A PRA Clinical Trial Manager leads and manages the execution of one or more clinical studies from study startup through database release. As a core…
Blog
Wearable Technology Introduces New Capabilities to Clinical Trials
Wearable devices are an essential part of our everyday lives. If you don’t own an Apple Watch or a Fitbit, chances are you know someone who does.…